Skip to main content
TiumBio Co., Ltd. logo

TiumBio Co., Ltd. — Investor Relations & Filings

Ticker · 321550 ISIN · KR7321550006 KO Professional, scientific and technical activities
Open in API
Filings indexed 296 across all filing types
Latest filing 2025-02-13 Legal Proceedings Report
Country KR South Korea
Listing KO 321550

About TiumBio Co., Ltd.

http://www.tiumbio.com/en/

TiumBio is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for rare and incurable diseases. The company's pipeline targets conditions with high unmet medical needs, including fibrotic diseases, cancer, and rare hematological disorders. Its lead assets include Merigolix (TU2670), an oral GnRH antagonist in clinical development for endometriosis and uterine fibroids, and TU7710, a long-acting recombinant activated factor VII for hemophilia. TiumBio also develops small molecule antagonists targeting the TGF-β signaling pathway for applications in oncology and fibrosis. The company advances its programs through clinical development and strategic global partnerships.

Recent filings

Filing Released Lang Actions
파생상품거래손실발생
Legal Proceedings Report Classification · 100% confidence The document is a regulatory disclosure regarding a derivative trading loss (파생상품거래손실발생) filed by TiumBio. It details the nature of the loss, the impact on equity, and the cause (valuation of convertible bonds and preferred shares). As this is a specific regulatory disclosure of a financial event that does not fit into categories like earnings releases or annual reports, it is classified as a general regulatory filing.
2025-02-13 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (TiumBio) announcing a significant change (over 30%) in revenue or profit structure compared to the previous fiscal year. This is a standard disclosure requirement in the Korean market (DART system) for preliminary financial results. Since it provides key financial highlights and reasons for the variance rather than a full annual report or a simple announcement of a report's availability, it falls under the Earnings Release category. FY 2024
2025-02-12 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 1,000 characters) regarding the scheduling and logistics of an upcoming Investor Relations (IR) meeting. It provides the date, time, location, and purpose of the event, and mentions that materials will be posted on the company website and the KRX system. Since it is an announcement of an event rather than the presentation materials themselves, and it does not fit into specific categories like 'Call Transcript' or 'Annual Report', it is classified as a Regulatory Filing (RNS) as it serves as a formal notice to the market.
2025-01-21 Korean
합병등종료보고서(합병)
M&A Activity Classification · 100% confidence The document is a 'Report of Completion of Merger' (합병등종료보고서) filed by TiumBio. It details the finalization of a merger process, including the timeline, share issuance, shareholder voting results, and post-merger financial status. This falls under M&A activity documentation, specifically the finalization phase of a merger, which is categorized as TAR (M&A Activity).
2024-12-27 Korean
합병등종료보고서(자산양수도)
M&A Activity Classification · 100% confidence The document is a '합병등종료보고서' (Report on the Completion of Merger, etc.), which specifically details the completion of a corporate asset disposal (sale of shares in SK Plasma). This falls under M&A-related activities, specifically the finalization of a transaction. Given the provided categories, 'TAR' (M&A Activity) is the most appropriate classification for documents detailing the completion of asset transfers or mergers.
2024-12-26 Korean
전환가액의조정
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing regarding the adjustment of the conversion price of convertible bonds (전환가액의 조정) for the company TiumBio. This type of disclosure relates to changes in the company's capital structure and financial instruments, specifically affecting the conversion price and the number of shares issuable upon conversion. According to the provided definitions, this falls under 'Capital/Financing Update' (CAP), as it details changes to financing terms.
2024-12-23 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.